Long-Term Acid Reflux Drug Use Linked to Anemia and Osteoporosis Risks

Popular acid reflux medications such as Prilosec, Nexium, and Protonix may pose hidden risks when used long term, according to a new study in rats that found prolonged use disrupted iron and calcium levels, raising concerns about anemia and osteoporosis. The research, published in a peer-reviewed journal and reported by Accident and Trauma News via ScienceDaily on February 26, 2026, observed mineral imbalances across multiple organs in animals administered proton pump inhibitors (PPIs) over extended periods. While experts affirm the drugs’ effectiveness for treating gastroesophageal reflux disease (GERD) and related conditions, they caution that unsupervised, long-term use could lead to unintended health consequences.

The study, conducted by researchers at a medical institution whose name was not disclosed in the source summary, tracked groups of rats given daily doses of omeprazole (the active ingredient in Prilosec and Nexium) or pantoprazole (the active ingredient in Protonix) for durations equivalent to several years in human use. Blood and tissue analyses revealed significantly reduced serum iron levels and altered calcium distribution in bones, kidneys, and the liver. These changes mirrored patterns seen in iron-deficiency anemia and early-stage bone density loss, conditions that in humans can progress to chronic fatigue and increased fracture risk.

Beyond blood markers, researchers noted shifts in mineral balance across multiple organ systems, including decreased zinc concentrations in the liver and altered magnesium uptake in the intestines. Such disruptions may interfere with enzymatic functions vital to metabolism and immune response, though the study did not establish direct causation for clinical disease in rats. The authors emphasized that their findings reflect biological changes associated with risk, not confirmed diagnoses of anemia or osteoporosis in the animal subjects.

Proton pump inhibitors work by blocking the hydrogen-potassium ATPase enzyme in stomach lining cells, thereby reducing gastric acid production. They are among the most widely prescribed medications globally, with millions of Americans using them regularly for heartburn, peptic ulcers, and Barrett’s esophagus. While short-term use is generally considered safe, guidelines from the American Gastroenterological Association and the U.S. Food and Drug Administration recommend limiting PPI therapy to the lowest effective dose for the shortest duration necessary, particularly for over-the-counter formulations.

Previous observational studies in humans have linked long-term PPI use to micronutrient deficiencies, including vitamin B12, magnesium, and calcium, as well as increased risks of Clostridioides difficile infection, kidney disease, and certain fractures. However, confounding factors such as age, comorbidities, and concurrent medications make it difficult to isolate the drugs’ direct effects. The current rat study helps address this limitation by controlling for external variables, offering a clearer view of PPIs’ physiological impact — though results in rodents do not always translate directly to humans.

Medical experts stress that patients should not discontinue prescribed PPIs without consulting a healthcare provider, as untreated acid reflux can lead to esophageal strictures, Barrett’s esophagus, or adenocarcinoma. Instead, they recommend periodic review of medication necessity, lifestyle modifications such as weight management and avoiding trigger foods, and consideration of alternative therapies like H2 blockers for intermittent symptoms. For those requiring long-term PPI therapy, monitoring of iron, calcium, and vitamin B12 levels may be advisable under medical supervision.

The study’s authors called for further research to determine whether the observed mineral shifts in rats correlate with clinical outcomes in humans, particularly in populations already at risk for osteoporosis or anemia, such as postmenopausal women or individuals with gastrointestinal disorders affecting nutrient absorption. They also urged pharmaceutical regulators to consider long-term safety data when evaluating label warnings and prescribing guidelines for PPIs.

As of the report date, no regulatory actions have been announced based on this specific study. The findings contribute to an evolving understanding of the systemic effects of widely used medications and underscore the importance of balancing therapeutic benefits with potential long-term risks, especially in chronic conditions requiring ongoing treatment.